Skip to content

Deep brain stimulation(DBS) for intractable obsessive-compulsive disorders(OCDs). randomized crossover trial and open-label trial

Deep brain stimulation(DBS) for intractable obsessive-compulsive disorders(OCDs). randomized crossover trial and open-label trial - Deep brain stimulation for intractable obsessive-compulsive disorders (DBS for OCDs)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000022969
Enrollment
20
Registered
2016-07-07
Start date
2016-07-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intractable obsessive-compulsive disorders

Interventions

Deep brain stimulation group Sham deep brain stimulation group

Sponsors

Hamamatsu University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 20 to 70 year-old OCD patients diagnosed by DSM-5 with the informed consent. Y-BOCS score of 30/40 or more and Global Assessment of Functioning scores of 45 or less. Refractory against medication and cognitive behavioral therapy for more than 5 years.

Exclusion criteria

Exclusion criteria: Other psychiatric illness (autism, schizophrenia, bipolar disorders, depression, drug addiction), and brain disease (epilepsy, trauma, cerebro-vascular disease, neuro-degenerative disease) except tic and Tourette syndrome. Severe cardiac diseases, pulmonary diseases blood diseases Pregnant or during breast-feeding. Whom researchers judged as inappropriate

Design outcomes

Primary

MeasureTime frame
more than 35% improvement of Yale Brown Obsessive Compulsive Scale (Y-BOCS) at 12 months after the initiation of AIC/VS-DBS.

Countries

Japan

Contacts

Public ContactKenji Sugiyama

Hamamatsu University School of Medicine Department of Neurosurgery

kesugi@hama-med.ac.jp053-435-2283

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026